CA Patent

CA2140542A1 — Oligonucleotide alkylphosphonothioates

Assigned to Aceragen Inc · Expires 1994-02-03 · 32y expired

What this patent protects

2140542 9402499 PCTABScor01 The invention provides improved oligonucleotides having greater resistance to nucleolytic degradation by virtue of having alkylphosphonothioate or arylphosphonothioate internucleotide linkages.

USPTO Abstract

2140542 9402499 PCTABScor01 The invention provides improved oligonucleotides having greater resistance to nucleolytic degradation by virtue of having alkylphosphonothioate or arylphosphonothioate internucleotide linkages.

Drugs covered by this patent

Patent Metadata

Patent number
CA2140542A1
Jurisdiction
CA
Classification
—
Expires
1994-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Aceragen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.